Skip to main content

CCTG Connection



Published:
Category: Group updates
The Canadian Cancer Trials Group 2018 Annual Spring Meeting of Participants will be held April 27 - 29, 2018 at the Chelsea Hotel in Toronto.
 
Invitations 
Read More

Published:
Category: Group updates

CCTG is launching the New-Investigator Cancer Trials Practicum to provide better engagement and training of new investigators with practical work in the field to allow for succession planning of top cancer trialists.

Read More

Published:
Category: Group updates

The Central Operations and Statistics Office is seeking nominations for the 2018 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.

We are seeking nominations for the following Recognition Awards:

Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research

Read More

Published:
Category: Publications
SC23: A Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases.
To compare the effectiveness of prophylactic dexamethasone versus placebo in protecting
Read More

Published:
Category: Trials

The CCTG HN.9 study has been centrally activated in Canada, as of January 31.

HN.9  is a Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), 2018.

Read More

Published:
Category: Trials
The MAP3 trial is considered permanently closed. MAP3 is a Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
For further information please contact Christine Bertrim
Read More



Published:
Category: Group updates
Clinical Research Associate (CRA) Volunteers Needed for Disease Site Executive Committees!

The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Lung Disease Site Committee Executive and the Quality of Life Committee.

Read More

Published:
Category: News
Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy. There is an urgent need to collaborate on clinical trials and translational research and to unite leading experts.

Read More